Scrip Awards 2021

Vaidheesh Annaswamy

Chief Executive Officer
North Star Asia LLP

Strong business leadership track record of over 35 years in healthcare and FMCG industries in multi countries focusing on sustainable and responsible growth in J&J and GSK. Currently CEO North Star Asia LLP, Management Consultant and Senior Advisor, PAG Holdings Hong Kong.

Mr. Vaidheesh was also previously MD and VP (South Asia), GSK. Created new business models and markets, turned around declining businesses, flourished in various leadership situations.

Winner of Economics Times award as the “Most Promising Asian Leader of the year -2016”. Won the prestigious Michel Porter award for “Shared value-2016”. President of OPPI 2017-2020. Winner of the prestigious Fair business practices Trophy. Signed and executed MOU with China Communist Party School for health care initiatives for J&J. Honorary Fellow of the Minimal Access Surgeons Association of India.

Bill Bishop

Principal
Bishop & Associates

Bishop & Associates is an independent consultancy serving the pharmaceutical, biotechnology, and medtech sectors.

Bishop retired from Becton Dickinson (BD) in 2017. He has served as Chair of Pharma Delegates and Chair of the American Chamber of Commerce Healthcare Committee and Lecturer at Temple University. Bishop has served on Leadership Teams as a Senior Executive for both Eli Lilly & Company and Wyeth (Pfizer) in Japan.

His extensive experience in the pharmaceutical industry includes building and managing functions, including: Government/Industry Relations; Communications; Branding; CSR; Issue/Crisis Management; Stakeholder Management; Advocacy; and the critical core capabilities of Market Access, Pricing, and Reimbursement.

Laura Brown

Director
LB Training and Development

Brown is an independent pharmaceutical project management, QA and training consultant, and course director for the MSc programme in clinical research at the University of Cardiff’s School of Pharmacy.

She has more than 20 years of experience of managing clinical development projects, and training in the pharmaceutical industry. She has worked in project management for several companies including Wellcome, Hoechst Marion Roussel, Good Clinical Research Practices and LB Training and Development.

She is also co-author of several books including, Project Management for the Pharmaceutical Industry.

Dr Ajit Dangi

Founder, President & CEO
Danssen Consulting

Danssen Consulting is a strategy firm specialising in Life Sciences and Healthcare.

Dr. Dangi has served as the Chairman of the Board of Fulford India Ltd., a subsidiary of Merck & Co. Inc. USA for ten years. He is also Director of Atul Bioscience Ltd. India. Dr. Dangi has served as President & Executive Director of Johnson & Johnson India Ltd, where he worked for twenty years in various capacities. He has also served as Director General of Organisation of Pharmaceutical Producers of India (OPPI) for over seven years.

Dr. Dangi is a Graduate in Chemistry from University of Bombay and later earned his Masters and Doctorate ( Ph.D. ) degrees in Pharmaceutical Chemistry from University of London , England . He has also undergone Advanced Management Program from Kellogg Graduate School of Business, Chicago, USA.

Laurie A. Halloran

CEO & Chairwoman of the Board
Halloran Consulting Group

Laurie founded Halloran Consulting Group in 1998 and has grown the business from a start-up to a highly regarded national consultancy with over 150 clients. These clients range from pre-funded startups who require regulatory and organizational growth strategies to global life science companies who need expertise managing product development challenges. She is able to draw additional expertise from her team in identifying and solving questions around strategy, regulatory, quality, organizational efficiency, complaint handling, human factors, manufacturing, medical affairs and compliance issues.

Earlier in her career, Halloran worked in the outsourcing services realm during PAREXEL International's rapid growth phase. She later led clinical development at OXiGENE and Antigenics. Her advisory Board positions include Boston University's School of Public Health, Leslie University Alumni Advisory Board, and Merck/EMD Serono's Precision Medicine. She also serves on the New England Women in Science Executive's Board of Directors.

Halloran has taught at George Washington University and Harvard University, and currently lectures at Boston University Medical School and the Tufts Center for Drug Development Post-Graduate program.

Brian Hargreaves

Independent Adviser
Former Pharma exec and biotech VC with 3i plc

Hargreaves is an independent adviser for private equity. His career in healthcare spans academia, pharma, venture capital and private equity.

Following his early career as a lecturer in pharmacy at Manchester University, he had a series of commercial and international marketing roles with Smith Kline and French, Mundipharma, Wellcome, Glaxo Wellcome and with Astra Hässle which included the commercialisation of the blockbuster Nexium. In 1997, he moved to 3i plc in the innovative growth period of biotech venture capital. More recently he originated several significant growth capital deals and buyouts.

Hargreaves currently advises selected private equity firms and spends a proportion of his time in the charity sector.

Dr. Annalisa Jenkins

Chair of The Court
The London School of Hygiene and Tropical Medicine

Dr. Annalisa Jenkins is a life sciences thought leader with over 20 years of biopharmaceutical industry experience. Prior to joining PlaqueTec CEO in November 2017, Jenkins served as president and CEO of Dimension Therapeutics,a leading gene therapy company that was acquired by Ultragenyx in November 2017.

Prior leadership roles have included the head of global research and development and executive vice president global development and medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years-including serving as senior vice president and head of global medical affairs. Earlier in her career, Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander.

Jenkins is a board member of several growing companies, including Ardelyx, Inc., iOX Therapeutics Limited, Thrombolytic Strategies Incorporated, PhESi, Oncimmune, Cocoon Biotech Inc. (Non Executive Chair), Cellmedica (Non-Executive Chair), Vium, Inc.(Executive Chair), and Silence Therapeutics (Non-Executive Chair). She also is a committee member of the Science Board to the U.S. FDA, and serves on the board of the Center for Talent Innovation in the U.K.

Prof. Trevor M Jones CBE FMedSci

Director
Arix Bioscience

Jones is a Director of the Life Science Investment Company Arix Bioscience plc. and the Oxford-based AI Drug Discovery Company e-Therapeutics.

He was formerly R&D director of The Wellcome Foundation, a director of Allergan Inc. and director general of the Association of the British Pharmaceutical Industry (ABPI). He is a visiting professor at King’s College, London.

Alison Messom

Chairman, Institute of Clinical Research
Director ALM Consultancy

Since 2012, Messom has been chairman of the Institute of Clinical Research; the oldest independent membership-led professional body for global clinical researchers. With a background in molecular genetics, Messom has almost 20 years’ industry experience working both within pharmaceutical companies and clinical research organisations.

Messom has detailed experience of directing global clinical trials and has worked in a wide variety of leadership roles, within pharma companies and CROs not only for project and monitoring teams, but also data management, outsourcing, informatics and translational medicine departments. Most recently she has provided consultancy support to an academic group working on a translational medicine project and operational consultancy to a mid-sized pharma company working in Phase III and IV.

Peter Pitts

President
Center for Medicine in the Public Interest

Peter Pitts is a former member of the United States Senior Executive Service, Pitts was the FDA’s associate commissioner for external relations, serving as senior communications and policy adviser to the commissioner. He supervised the FDA's Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. He served on the agency’s obesity working group and counterfeit drug taskforce and as a Special Government Employee consultant to the FDA’s Risk Communications Advisory Committee.

His specific areas of global policy expertise include FDA policy and process, healthcare technology assessment and reimbursement issues, real-world evidence, social media, off-label communications, pharmacovigilance, patient-focused drug development, abuse-deterrent opioids, biosimilar development, Rx-to-OTC switching, risk management plans, GMP policies, drug safety, Critical Path, personalized medicine, clinical trial transparency, IP protection, FDA reform, drug importation and counterfeiting.

Andy Smith

Director, Analyst
Edison Investment Research

Smith began his career as a scientist in the research and development division of ICI and then SmithKline Beecham. After completing his PhD in Molecular Biology at the University of Nottingham and Glaxo, and after then an MBA, Smith switched to a commercial role at SB Pharmaceuticals and was appointed global brand manager for Bactroban and new products in Anti-Infectives Strategic Product Development (SPD). In 2000, Smith moved into asset management and venture capital at 3i Group and subsequently held the position of lead fund manager for four life science specific funds – 3i Bioscience Investment Trust PLC, International Biotechnology Trust PLC, and AXA Framlington Biotech Fund. Smith was awarded the Techmark technology fund manager of the year for 2007.

After leaving AXA in 2010, Smith held appointments as director of business development at the Oxfordshire Bioscience Network and head of corporate finance at PharmaVentures. Smith has also taught the life science company valuation, finance and analysis module on the University of Cambridge MPhil program for over ten years. Smith returned to specialist fund management in 2012 to manage the Magna Biopharma Income Fund.

In 2017 Andy moved to the Pricing & Market Access group at ICON in London where he advised big pharma and smaller life science companies on the valuation and commercialisation of their products and returned to the City at the end of 2017 to work at Edison.

Robert Spiegel

Founder
Spiegel Consulting

Spiegel Consulting is an independent advisory firm to pharma and biotechnology companies.

Spiegel retired in 2009 as chief medical officer at Schering-Plough. With more than 25 years of experience in the pharmaceutical industry he played a significant role in the development of novel biologics and drugs as senior vice-president of Worldwide Clinical Research.

Spiegel is a fellow of the American College of Physicians and has received numerous awards and fellowships. He serves as an advisor to Warburg Pincus and the Israeli Biotech Fund and on the boards of numerous biotechnology companies and non-profit organizations. He is an assistant professor Weill Cornell Medical School and associate fellow in the University of Pennsylvania Center for Bioethics.

Brian Tempest

Editor in Chief
Journal of Generic Medicines

Tempest has worked in the pharmaceutical industry for the last 46 years and in that time has managed healthcare businesses around the globe. Between 1995 and 2007 he held senior executive positions, including president, CEO and vice-chairman at Ranbaxy Laboratories.

Previously, Tempest was Far East regional director for GlaxoSmithKline in the Far East, Middle East and Africa.

Today, as Chairman of Hale & Tempest, he advises companies, banks, investment funds, private equity and high net-worth individuals on their strategy in Asia.

Tempest is a non-executive director of SRL Diagnostics, Fortis Healthcare, Touch Digital Media, Religare Capital Markets, Glenmark Pharmaceuticals and United Nations Medicines Patent Pool.

Viren Mehta

Mehta founded and is managing member of Mehta Partners, LLC. His analytical insights on global healthcare have influenced bio-pharmaceutical strategy and investments worldwide.

Educated at the University of Southern California and UCLA, he has worked with senior biopharma leaders and investment managers for over 30 years. Mehta’s career began with Merck & Co. in international strategic planning and competitor analysis. This foundation prompted Wood MacKenzie & Company Inc. to invite him to establish a pharmaceutical research function in New York. This effort was expanded at S.G. Warburg & Company, and led to the formation of the BioPharma investment advisory group Mehta and Isaly, now known as Mehta Partners.

Gather Health is Mehta‘s new initiative to empower patients while enhancing physician productivity. Gather Health brings together healthcare providers and patients’ social networks, enabling patients to get real-time and active resources and motivation to improve outcomes.

Phornvit Phacharintanakul

Phacharintanakul is chair of Strategic Business Partners in Bangkok, Thailand. Until the end of 2004 he was chair of the board at Aventis Thailand, where he previously held a range of posts including managing director and marketing manager. Before joining Aventis, he was on the secretariat of the United Nations Economic Commission for Asia and the Pacific. Phacharintanakul also acts as an expert advisor for the Thailand Center of Excellence for Life Sciences.